CJC (No DAC) + IPA Blend 10mg · single vial
CJC-1295 + Ipamorelin is a research peptide combination consisting of a modified growth hormone-releasing hormone (GHRH) analog and a selective growth hormone secretagogue. CJC-1295 targets the GHRH receptor (GHRHR), while Ipamorelin activates the ghrelin receptor (GHS-R1a).
Certificate of Analysis
Compound information
What is CJC-1295 (No DAC)?
A modified 29-amino-acid form of growth-hormone-releasing hormone, also called Modified GRF(1-29). Four changes to its sequence keep it from breaking down quickly while holding its short, pulse-like action. In this blend it is pre-mixed with the Ipamorelin in a single vial.
Structure
Stability information
What is Ipamorelin?
A five-amino-acid peptide that acts on the ghrelin receptor to prompt growth-hormone release. It is known for being selective, mostly leaving cortisol and prolactin alone. In this blend it is supplied pre-mixed with the GHRH analog in one vial at a fixed ratio.
Structure
Stability information
Product overview
A single-vial growth-hormone research blend supplied at a ≥99% HPLC analytical standard per compound.
Technical overview
This CJC-1295 + Ipamorelin blend combines two peptides that reach growth-hormone release through different receptors, pre-mixed in a single vial at a fixed ratio. CJC-1295 without DAC acts at the GHRH receptor, while Ipamorelin acts at the ghrelin receptor. Pre-mixing them fixes the ratio, so one reconstitution yields a single solution carrying both compounds.
Each lot is released against a lot-matched Certificate of Analysis carrying HPLC purity and LC-MS identity.
Research applications
The blend suits work that studies the two pathways together. With both compounds in one solution at a fixed ratio, it supports dual-receptor signaling assays, cAMP and calcium-response measurements in pituitary cell models, and combined-stimulation designs with a single preparation step.
Kylo Peptides supplies this compound as a reference material for scientific inquiry. All applications must be conducted by qualified professionals in controlled laboratory environments. It has not been evaluated by the FDA and is not intended to diagnose, treat, cure, or prevent any disease.
Frequently Researched Together
Frequently Asked Questions
Same two peptides, different format. The blend combines CJC-1295 without DAC and Ipamorelin in one vial at a fixed ratio, while the stack supplies each in its own vial. The stack lets you set each compound separately; the blend keeps both in a single, ready-mixed preparation.
One vial: CJC-1295 without DAC and Ipamorelin pre-mixed at a fixed ratio, lyophilized and sealed. Reconstitute once and both compounds are in the same solution.
The two act through different receptors, so pairing them is a common study design. The blend fixes the ratio and puts both in one vial, so a single reconstitution yields one solution with both compounds, with less handling and fewer vials to track.
Yes. Every lot ships with a lot-matched Certificate of Analysis showing HPLC purity and LC-MS identity. You verify it against the lot number on the vial.
Both the same way: keep the lyophilized powder at −20 °C, sealed, dry, and out of light, with −80 °C for longer storage. Once a vial is reconstituted, hold that solution at 2 to 8 °C, use it within a validated window, and avoid repeated freeze-thaw cycles.
When a study needs the two compounds set independently. Separate vials make it possible to change the timing or proportion of each; a blend fixes them in one ratio. If that ratio needs to vary, the stack is the better fit.
Backed By Lot-Matched COAs
Every vial ships with a certificate of analysis matched to its exact lot.
Shop catalog →
